Top Tweets for #MONALEESA3
3. #MONALEESA3 Update at ESMO Breast
- Ph3, #Ribociclib + fulvestrant, 1L advanced/metastatic HR+ve .
- Updated OS at mFU 70.8mos: mOS 67.6mos Vs 51.8mos
- OS improved by 15.8 mos (HR 0.67)
@myESMO #bcsm
Oncology Earnings Report: #PracticeChanging studies/approvals for 2nd Quarter, 2022 🧵
1. #RATIONALE309 1L rec/met NPC
2. #monarchE Update - ESMO Breast
3. #MONALEESA3 Update - ESMO Breast
4. #DB03 TDxD approved 2L Her2+ mBC
#OncEd #MedTwitter @OncoAlert #OncTwitter #bcsm
#MONALEESA3 trial at median follow up of 70.8 months (!!) presented at #ESMObreast22: exciting to see another trial showing median #OS beyond 5 years in patients with metastatic endocrine sensitive HR+ #HER2- #BreastCancer receiving #ET + #ribociclib @tmhmedoncalumni @ACTREC_TMC
Updated OS at mFU 70.8mos for #MONALEESA3:
- Ph3, #Ribociclib + fulvestrant, 1L advanced/metastatic HR+ve .
- mOS 67.6 mos Vs 51.8mos
- OS improved by 15.8 mos (HR 0.67)
#ESMOBreast22 #BCSM @OncoAlert #OncEd #OncTwitter
Slides shared by @matteolambe and @Icro_Meattini
Updated data from #MONALEESA3 trial at median follow up of 70.8 months (!!) presented at #ESMObreast22: exciting to see another trial showing median #OS beyond 5 years in patients with metastatic endocrine sensitive HR+ #HER2- #BreastCancer receiving #ET + #ribociclib
@OncoAlert
Michelino De Laurentiis, intervistato da @angela_toss, commenta l'aggiornamento dei dati del MONALEESA3 presentati ad ASCO 2021
https://t.co/z5GjgBo6qt
#ASCO2021 #breastcancer #MONALEESA3
'Reassuring' New #BreastCancer Survival Data on #Fulvestrant Plus #CDK4/6 Inhibitors
— Our expert roundtable discusses the overall survival updates from #PALOMA3 and #MONALEESA3
@hoperugo MD
@JenniferLitton MD
@DrWGradishar MD
https://t.co/KvGEnypAaD
@medpagetoday
#ASCO21 | #MONALEESA3: the OS benefit of RIB was observed in the 1L and 2L subgroups, which further supports the use of RIB in these populations. A comment by Michelino De Laurentiis. @istitutotumori
Reassuring updates CDK4/6i #PALOMA3 & #MONALEESA3 survival & safety of #Palbociclib & #Ribociclib in pts with #breastcancer. 4th CDK4/6i #Dalpiciclib should make @ASCOPres happy: help equity by increasing competition & lowering CDK4/6i prices #ASCO21 @MCristofanill @breastoncdoc
We just reviewed updates on #PALOMA3 and #MONALEESA3, two studies that forever changed the landscape & standard of care in metastatic breast cancer—made possible by 1,247 volunteers who participated in the two studies.
THANK YOU CLINICAL TRIAL PARTICIPANTS #ASCO21 @OncoAlert
After #PALOMA3, also the updated data from #MONALEESA3 confirming longterm benefit in OS after longer follow-up (>4years!) Reassuring longterm follow-up data with CDK4/6i + fulvestrant in patients with metastatic breast cancer! #ASCO21
Metastatic #BreastCancer Oral Abstract Session at #ASCO21: not clear to me this slide from #MONALEESA3...it seems that patients with secondary endocrine resistance were included in the "endocrine-sensitive population"...how to interpret it?
@OncoAlert #bcsm @ASCO
#MONALEESA3 #ASCO21 #bcsm
Dr. Slamon
🔹mOS 53.7 months vs 41.5 months
🔹5 year OS 46% vs 31%
🔹All subgroups benefit
🔹longer chemo free survival, longer times to first chemo
🔹EFFECT MAY BE DURABLE 💡(PFS2)
Metastatic #BreastCancer Oral Abstract Session at #ASCO21: final analysis of #MONALEESA3 (#fulvestrant with or without #ribociclib)...really great data but please don't stop trial follow-up with median #OS not yet reached in first-line treated patients
@OncoAlert #bcsm @ASCO
#ASCO21 Abstract 1001
Updated OS results from #MONALEESA3 with fulvestrant +/- #ribociclib
mOS 53,7 vs 41,5mo (HR 0.72)
HR 0.64 in 1⃣L
HR 0.78 in 2⃣L
Benefit consistent across subgroups
@OncoAlert #bcsm
#ESMO19 | Lo studio #MONALEESA3 ha indagato l’efficacia di un trattamento con #ribociclib e #fulvestrant in prima e seconda linea nel carcinoma mammario in post-menopausa. Ne abbiamo discusso con Michelino De Laurentiis [@istitutotumori]: https://t.co/bXQWqZQzgd
![Oncoinfo_it's tweet photo. #ESMO19 | Lo studio #MONALEESA3 ha indagato l’efficacia di un trattamento con #ribociclib e #fulvestrant in prima e seconda linea nel carcinoma mammario in post-menopausa. Ne abbiamo discusso con Michelino De Laurentiis [@istitutotumori]: https://t.co/bXQWqZQzgd https://t.co/lcggN7qC5G](https://pbs.twimg.com/media/EFubRqKWoAIueKO.jpg)
Dennis Slamon at #ESMO19 presents #MONALEESA3 results improved #OverallSurvival 1st line and 2nd line Metastatic #breastcancer
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
119.2M followers
Cristiano Ronaldo
@cristiano
112.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.1M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.3M followers
KATY PERRY
@katyperry
88.6M followers
Taylor Swift
@taylorswift13
82.5M followers
Lady Gaga
@ladygaga
74M followers
Virat Kohli
@imvkohli
71.3M followers
Kim Kardashian
@kimkardashian
70.2M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.4M followers
Neymar Jr
@neymarjr
64.2M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.7M followers
X
@x
60.8M followers